https://www.prnewswire.com/news-releases/european-medicines-agency-accepts-samsung-bioepis-enbrelr-biosimilar-candidate-sb4-for-regulatory-review-300023409.html
European Medicines Agency Accepts Samsung Bioepis' Enbrel(R) Biosimilar Candidate, SB4, for...
/PRNewswire/ -- Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for its Enbrel (etanercept) biosimilar...
european medicines agencysamsung bioepis
https://www.biospace.com/press-releases/samsung-bioepis-releases-first-quarter-2025-us-biosimilar-market-report
Samsung Bioepis Releases First Quarter 2025 US Biosimilar Market Report - BioSpace
samsung bioepisfirst quartermarket reportreleases
https://www.businesswire.com/news/home/20260318208482/nl
Samsung Bioepis sluit een partnerschapsakkoord met Sandoz voor in totaal vijf biosimilaire...
samsung bioepis
https://www.fiercebiotech.com/keyword/samsung-bioepis
Samsung Bioepis | Fierce Biotech
samsung bioepisfiercebiotech